Trials / Recruiting
RecruitingNCT06757881
IL1RAP-targeting Chimeric Antigen Receptor T Cells in the Treatment of Relapsed/Refractory Hepatocellular Carcinoma
A Phase 1 Study of IL1RAP-targeting Chimeric Antigen Receptor T Cells in the Treatment of Relapsed/Refractory Hepatocellular Carcinoma
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 18 (estimated)
- Sponsor
- Shanghai Zhongshan Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
A Phase 1 Study of IL1RAP-targeting Chimeric Antigen Receptor T cells in the Treatment of Relapsed/Refractory Hepatocellular Carcinoma
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Gene modified anti-IL1RAP Chimeric Antigen Receptor T Cells :1.0×10^8(First dose group) | Different dose groups |
| BIOLOGICAL | Gene modified anti-IL1RAP Chimeric Antigen Receptor T Cells :2.5×10^8(Second dose group) | Different dose groups |
| BIOLOGICAL | Gene modified anti-IL1RAP Chimeric Antigen Receptor T Cells :5.0×10^8（Third dose group） | Different dose groups |
Timeline
- Start date
- 2025-01-01
- Primary completion
- 2026-12-01
- Completion
- 2027-12-01
- First posted
- 2025-01-03
- Last updated
- 2026-01-08
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06757881. Inclusion in this directory is not an endorsement.